BioNTech Ownership

Who are the major shareholders and have insiders been buying or selling?


Recent Insider Transactions

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

What is the ownership structure of 22UA?
Owner TypeNumber of SharesOwnership Percentage
Private Companies2,4800.00103%
Individual Insiders44,128,29318.4%
General Public45,171,23418.8%
Institutions47,948,64420%
VC/PE Firms102,489,10142.8%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 76.24% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
42.8%
AT Impf GmbH
102,489,101CHF 11.2b-1.5%no data
17.2%
Ugur Sahin
41,295,728CHF 4.5b0%no data
3.43%
Baillie Gifford & Co.
8,220,581CHF 897.3m-1.05%0.41%
2.49%
FMR LLC
5,979,545CHF 652.7m770%0.04%
1.88%
PRIMECAP Management Company
4,516,518CHF 493.0m-5.7%0.36%
1.84%
Flossbach & Von Storch Vermoegensmanagement AG
4,406,843CHF 481.0m1.08%1.27%
0.86%
BlackRock, Inc.
2,071,934CHF 226.2m9.31%no data
0.81%
Capital Research and Management Company
1,951,606CHF 213.0m-0.09%0.01%
0.75%
Temasek Holdings (Private) Limited
1,807,232CHF 197.3m0%0.17%
0.5%
Salvia GmbH
1,193,651CHF 130.3m0%no data
0.39%
Candriam, Société En Commandite Par Actions
927,164CHF 101.2m60.1%0.31%
0.38%
Ozlem Tureci
913,247CHF 99.7m0%no data
0.34%
Sean Marett
815,263CHF 89.0m0%no data
0.31%
Sierk Poetting
754,784CHF 82.4m0%no data
0.27%
Morgan Stanley, Investment Banking and Brokerage Investments
653,618CHF 71.3m-41.2%0.01%
0.27%
Altrinsic Global Advisors, LLC
652,706CHF 71.2m-3.48%2.15%
0.26%
Balyasny Asset Management L.P.
620,466CHF 67.7m36.1%0.19%
0.21%
Fred Alger Management, LLC
500,844CHF 54.7m0%0.25%
0.21%
Acatis Anlageberatung fur Investmentfonds GmbH
492,832CHF 53.8m0%3.83%
0.2%
Deka Investment GmbH
481,397CHF 52.5m12.6%0.05%
0.19%
First Trust Advisors LP
451,192CHF 49.3m10.3%0.04%
0.17%
Quinn Opportunity Partners LLC
404,500CHF 44.2m-40.8%4.09%
0.17%
Voloridge Investment Management, LLC
400,306CHF 43.7m48.3%0.16%
0.16%
Point72 Asset Management, L.P.
389,238CHF 42.5m-15.7%0.11%
0.16%
abrdn plc
385,668CHF 42.1m70.7%0.04%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/07 20:33
End of Day Share Price 2025/02/07 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

BioNTech SE is covered by 31 analysts. 19 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ishan MajumdarBaptista Research
Harry GillisBerenberg
Zhiqiang ShuBerenberg